(Q41733328)

8 October 2017

1 reference

title

A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia (English)

1 reference

8 October 2017

P Ekman

1

1 reference

PubMed ID

9530536

8 October 2017

language of work or name

1 reference

1 March 1998

1 reference

8 October 2017

1 reference

8 October 2017

18

1 reference

8 October 2017

3

1 reference

8 October 2017

161-170

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-199818030-00002

8 October 2017

0 references

cites work

Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group

1 reference

12 December 2020

The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro.

1 reference

12 December 2020

Scandinavian Clinical Study of Finasteride in the Treatment of Benign Prostatic Hyperplasia

1 reference

12 December 2020

Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group

1 reference

12 December 2020

An economic evaluation of finasteride for treatment of benign prostatic hyperplasia

1 reference

12 December 2020

A Placebo-controlled Double-blind Study of the Effect of Phenoxybenzamine in Benign Prostatic Obstruction

1 reference

12 December 2020

Long-term effects of finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outflow obstruction due to benign prostatic hyperplasia

1 reference

12 December 2020

Maximum efficacy of finasteride is obtained within 6 months and maintained over 6 years. Follow-up of the Scandinavian Open-Extension Study. The Scandinavian Finasteride Study Group

1 reference

12 December 2020

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

1 reference

12 December 2020

Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia

1 reference

12 December 2020

Effects of Prazosin in Patients with Benign Prostatic Obstruction

1 reference

12 December 2020

Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia.

1 reference

12 December 2020

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

1 reference

12 December 2020

TREATMENT OF BENIGN PROSTATIC HYPERTROPHY WITH HYDROXYPROGESTERONE CAPROATE: EFFECT ON CLINICAL SYMPTOMS, MORPHOLOGY, AND ENDOCRINE FUNCTION.

1 reference

12 December 2020

The effect of finasteride on prostate specific antigen: review of available data

1 reference

12 December 2020

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

12 December 2020

Proscar: five-year experience.

1 reference

12 December 2020

Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism

1 reference

12 December 2020

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

1 reference

12 December 2020

Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetate

1 reference

12 December 2020

The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia

1 reference

12 December 2020

Gynecomastia and breast cancer during finasteride therapy

1 reference

12 December 2020

Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study

1 reference

12 December 2020

The Endocrine Control of the Prostate: (Section of Urology).

1 reference

12 December 2020

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

12 December 2020

Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia

1 reference

12 December 2020

Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group

1 reference

12 December 2020

10.2165/00002018-199818030-00002

Identifiers

DOI

1 reference

PubMed ID

9530536

Dimensions Publication ID

8 October 2017

0 references

1 reference

PubMed ID

9530536